Anlon Healthcare Files DRHP Again With SEBI for IPO

Anlon Healthcare Ltd has filed a draft red herring prospectus (DRHP) with the Securities and Exchange Board of India (SEBI) for the third time to raise funds through an Initial Public Offering (IPO). The company, which manufactures advanced pharmaceutical intermediates and active pharmaceutical ingredients (APIs), has retained the IPO structure and size from its previous filings.

Filing History

The company first submitted its draft papers in October 2024, which were returned by SEBI in December 2024. It filed the documents again on February 20, 2025, but later withdrew them on March 28 due to unstable market conditions. This is the third submission, and the company has not made any changes to the issue size.

Read more: SEBI Returns Anlon Healthcare’s IPO Draft Papers!

IPO Structure and Size

The proposed IPO will consist solely of a fresh issue of 1.4 crore equity shares. There is no offer-for-sale (OFS) component in this issue. Interactive Financial Services Ltd is the appointed merchant banker for the public offer.

Use of Funds

Proceeds from the IPO will be directed towards the expansion of the company’s manufacturing facility, repayment or prepayment of certain outstanding borrowings, meeting working capital needs, and general corporate requirements. The company has also mentioned the possibility of deploying funds for inorganic growth, though no specifics have been disclosed.

Company Profile

Anlon Healthcare is based in Gujarat and focuses on producing chemical components used in pharmaceutical formulations. Its product portfolio includes pharmaceutical intermediates and APIs used in manufacturing finished dosage forms like tablets, syrups, ointments, and capsules. These also have applications in nutraceutical, personal care, and veterinary products.

Financials

In the recent financial period, Anlon Healthcare reported a profit increase from ₹5.82 crore to ₹9.65 crore. However, revenue during the same period fell from ₹112.9 crore to ₹66.6 crore.

Conclusion

The company is continuing its plan to go public, keeping the IPO structure unchanged. Funds raised will be used across key operational areas, including manufacturing expansion and debt reduction.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.